Towards an Understanding of the Effect of Adding a Foam Core on the Blast Performance of Glass Fibre Reinforced Epoxy Laminate Panels.

This paper presents insights into the blast response of sandwich panels with lightweight foam cores and asymmetric (different thicknesses) glass fibre epoxy face sheets. Viscously damped elastic vibrations were observed in the laminates (no core), while the transient response of the sandwich panels was more complex, especially after the peak displacement was observed. The post-peak residual oscillations in the sandwich panels were larger and did not decay as significantly with time when compared to the equivalent mass laminate panel test.

Defining blast loading 'zones of relevance' for primary blast injury research: A consensus of injury criteria for idealised explosive scenarios.

Blast injuries remain a serious threat to defence and civilian populations around the world. 'Primary' blast injuries (PBIs) are caused by direct blast wave interaction with the human body, particularly affecting air-containing organs. Work to define blast loading conditions for injury research has received relatively little attention, though with a continued experimental focus on PBIs and idealised explosion assumptions, meaningful test outcomes and subsequent clinical applications, rely on appropriate simulated conditions.

Guidelines to inform the generation of clinically relevant and realistic blast loading conditions for primary blast injury research.

'Primary' blast injuries (PBIs) are caused by direct blast wave interaction with the human body, particularly affecting air-containing organs. With continued experimental focus on PBI mechanisms, recently on blast traumatic brain injury, meaningful test outcomes rely on appropriate simulated conditions. Selected PBI predictive criteria (grouped into those affecting the auditory system, pulmonary injuries and brain trauma) are combined and plotted to provide rationale for generating clinically relevant loading conditions.

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study.

P218 is a highly selective dihydrofolate reductase inhibitor with potent in vitro activity against pyrimethamine-resistant Plasmodium falciparum. This single-center, randomized, double-blind, placebo-controlled phase Ib study evaluated P218 safety, pharmacokinetics, and chemoprotective efficacy in a P. falciparum sporozoite (PfSPZ) volunteer infection study (VIS).